Literature DB >> 16208654

Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.

Michael M Ward1, Michael H Weisman, John C Davis, John D Reveille.   

Abstract

OBJECTIVE: To identify risk factors for functional limitations in patients with ankylosing spondylitis (AS) of at least 20 years' duration.
METHODS: Patients with AS for > or =20 years were enrolled in the cross-sectional component of the Prospective Study of Outcomes in AS. All patients had clinical evaluations and completed questionnaires on functional limitations and potential risk factors. Functional limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score range 0-100, higher scores indicate more limitations) and the Health Assessment Questionnaire for the Spondylarthropathies (HAQS). Risk factors included demographic characteristics, duration of AS, smoking status, number of comorbid medical conditions, recalled level of recreational activity in teens and twenties, occupational physical activity throughout life (rated 1 = little, 2 = moderate, 3 = heavy, and weighted by the number of years in each job), and history of AS in a first-degree relative.
RESULTS: The 326 patients (74% men) had a mean +/- SD age of 55.0 +/- 10.7 years, a mean duration of AS symptoms of 31.7 +/- 10.2 years, and a mean BASFI score of 40.7 +/- 25.6. BASFI scores increased with higher lifetime occupational physical activity (r = 0.31; P < 0.0001), the number of comorbid conditions (r = 0.25; P < 0.0001), and the duration of AS (r = 0.12; P = 0.04). BASFI scores were higher among current smokers compared with former/nonsmokers (55.5 versus 38.9; P = 0.0002), and among nonwhites compared with whites (49.9 versus 39.3; P = 0.02). In multivariable analyses, lifetime occupational physical activity, current smoking, education level, number of comorbid conditions, and family history were significantly associated with BASFI scores. The same risk factors were associated with the HAQS.
CONCLUSION: Functional limitations in patients with AS for >/=20 years are greater among those with a history of more physically demanding jobs, more comorbid conditions, and among smokers, and are less severe among those with higher levels of education and a family history of AS.

Entities:  

Mesh:

Year:  2005        PMID: 16208654      PMCID: PMC2530902          DOI: 10.1002/art.21444

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

1.  Functional disability predicts total costs in patients with ankylosing spondylitis.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2002-01

2.  Employment perspectives of patients with ankylosing spondylitis.

Authors:  A M J Chorus; A Boonen; H S Miedema; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

3.  Risk factors for work disability in patients with ankylosing spondylitis.

Authors:  M M Ward; S Kuzis
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

4.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors:  Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

Review 5.  The epidemiology of rheumatoid arthritis.

Authors:  S E Gabriel
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

Review 6.  Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review.

Authors:  A Boonen; H de Vet; D van der Heijde; S van der Linden
Journal:  J Rheumatol       Date:  2001-05       Impact factor: 4.666

7.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

8.  Assessment of functional ability in younger and older patients with ankylosing spondylitis: performance of the bath ankylosing spondylitis functional index.

Authors:  Albrecht Falkenbach; Annegret Franke; Astrid Van Tubergen; Sjef Van Der Linden
Journal:  Am J Phys Med Rehabil       Date:  2002-06       Impact factor: 2.159

9.  Predictors of the progression of functional disability in patients with ankylosing spondylitis.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

10.  Predictors of longterm outcome in ankylosing spondylitis.

Authors:  Michele F Doran; Sinead Brophy; Kirsten MacKay; Gordon Taylor; Andrei Calin
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

View more
  35 in total

1.  Ankylosing spondylitis: patterns of radiographic involvement--a re-examination of accepted principles in a cohort of 769 patients.

Authors:  Jennifer H Jang; Michael M Ward; Adam N Rucker; John D Reveille; John C Davis; Michael H Weisman; Thomas J Learch
Journal:  Radiology       Date:  2010-10-22       Impact factor: 11.105

2.  Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis.

Authors:  Michael M Ward; John D Reveille; Thomas J Learch; John C Davis; Michael H Weisman
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis.

Authors:  Michael M Ward; Matthew R Hendrey; James D Malley; Thomas J Learch; John C Davis; John D Reveille; Michael H Weisman
Journal:  Arthritis Rheum       Date:  2009-07-15

4.  The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis.

Authors:  Grigorios T Sakellariou; Athanasios D Anastasilakis; Eustathios Kenanidis; Michael Potoupnis; Eleftherios Tsiridis; Matthaios Savvidis; Nikolaos Kartalis; Fares E Sayegh
Journal:  Rheumatol Int       Date:  2015-10-16       Impact factor: 2.631

5.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

6.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 10 Patient information].

Authors:  U Kiltz; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

7.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; U Oberschelp; E Schneider; B Swoboda; H Böhm; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

8.  Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility.

Authors:  Chun-Hsiung Chen; Hung-An Chen; Chin-Li Lu; Hsien-Tzung Liao; Chin-Hsiu Liu; Chang-Youh Tsai; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2013-01-18       Impact factor: 2.980

9.  Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?

Authors:  Siddharth Bethi; Abhijit Dasgupta; Michael H Weisman; Thomas J Learch; Lianne S Gensler; John C Davis; John D Reveille; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

10.  Oral health-related quality of life is associated with disease specific parameters in patients with ankylosing spondylitis.

Authors:  Gerhard Schmalz; Donya Douglas; David Douglas; Susann Patschan; Daniel Patschan; Gerhard A Müller; Rainer Haak; Jan Schmickler; Dirk Ziebolz
Journal:  Clin Oral Investig       Date:  2018-02-07       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.